Literature DB >> 24700044

A rare cause of severe hepatomegaly with an improving outcome.

Line Godskesen1, Niels Abildgaard, Jens Kjeldsen, Aleksander Krag.   

Abstract

A previously healthy 43-year-old man presented with dyspnoea, 15 kg weight loss, severe hepatomegaly and alkaline phosphatase at 5400 U/L. Examinations seemed to suggest cirrhosis, but blood samples did not show any signs of underlying liver disease. Liver biopsy revealed amyloid light chain (AL) amyloidosis and bone marrow showed multiple myeloma (MM). The patient was treated with drugs of choice cyclophosphamide, bortezomib and dexamethasone. He responded well to the treatment and so far achieved partial response. Previously MM was associated with poor prognosis but due to improved treatment for AL the patient can achieve a progression-free period with good quality of life.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24700044      PMCID: PMC3987551          DOI: 10.1136/bcr-2013-203360

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

Review 1.  Multiple myeloma.

Authors:  Dean Smith; Kwee Yong
Journal:  BMJ       Date:  2013-06-26

2.  Systemic light chain amyloidosis: an update for treating physicians.

Authors:  Giampaolo Merlini; Ashutosh D Wechalekar; Giovanni Palladini
Journal:  Blood       Date:  2013-05-13       Impact factor: 22.113

Review 3.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

Authors:  Joseph R Mikhael; Steven R Schuster; Victor H Jimenez-Zepeda; Nancy Bello; Jacy Spong; Craig B Reeder; A Keith Stewart; P Leif Bergsagel; Rafael Fonseca
Journal:  Blood       Date:  2012-02-13       Impact factor: 22.113

5.  Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.

Authors:  Christopher P Venner; Thirusha Lane; Darren Foard; Lisa Rannigan; Simon D J Gibbs; Jennifer H Pinney; Carol J Whelan; Helen J Lachmann; Julian D Gillmore; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Blood       Date:  2012-02-13       Impact factor: 22.113

6.  Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973).

Authors:  A S Cohen; A Rubinow; J J Anderson; M Skinner; J H Mason; C Libbey; H Kayne
Journal:  Am J Med       Date:  1987-06       Impact factor: 4.965

Review 7.   Primary hepatic amyloidosis: a mini literature review and five cases report.

Authors:  Ya-Dong Wang; Cai-Yan Zhao; Hong-Zhu Yin
Journal:  Ann Hepatol       Date:  2012 Sep-Oct       Impact factor: 2.400

Review 8.  Al amyloidosis.

Authors:  Estelle Desport; Frank Bridoux; Christophe Sirac; Sébastien Delbes; Sébastien Bender; Béatrice Fernandez; Nathalie Quellard; Corinne Lacombe; Jean-Michel Goujon; David Lavergne; Julie Abraham; Guy Touchard; Jean-Paul Fermand; Arnaud Jaccard
Journal:  Orphanet J Rare Dis       Date:  2012-08-21       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.